Skip to main content
. 2015 Oct 8;47(6):2057–2063. doi: 10.3892/ijo.2015.3193

Figure 4.

Figure 4

Anti-angiogenic and antitumor activity of VASH1. (A) Growth curves of SKOV-3/LUC and SKOV-3/VASH1 subcutaneous tumors. (B) Immunohistochemical staining of new blood vessels in tumor tissue. (C) The microvessel area in SKOV-3/VASH1 tumors per high-power field was significantly lower than that in SKOV-3/LUC tumors. *p<0.01.